Dinakar Singh

The second was gene therapy with Alexis.

And the third is Roche.

which is just a sandwich you take every day.

That was incredible luck, I suppose.

But part of what we did from a time perspective, because we're desperately worried about the clock running out, was try and make sure that we could have everything in place so that when these drugs were ready, they could go 90 miles an hour.

And so, for example, we went to FDA through lots of relationships on the political side, both to get NIH moving, by the way, in the early days, and to help later on.

We got to know, if you will, all the relevant senators and congressmen that mattered when it came to drug development, NIH, and things like that.

And

Look, our view is just apparent with tears on their face.

It doesn't get very far.

But we would say, look, we want to be really supportive of you.

There's a chance here to actually achieve a success.

And that's why you should focus on this, not just because it's sad, but because it might be fixable.

And I think that became a powerful combination.

It took some work.

We, for example, got 50 top scientists who were Nobel Prize winners to sign a letter

talking about how there was a really good chance of successor.

We then started literally taking out full-page color ads in some of the political newspapers in Washington, Roll Call, Daily Herald, that sort of stuff, so that all the staffers would see this very striking Roll Call ad every day on this stuff.

Lots of stuff like that to really go and essentially create a real sense of momentum on the side, because it did occur to us that while at the end of the day, development of the drug

matter and getting companies involved with matter, everyone would move faster if they thought that the other guy was there too.